[1]
|
Beaufrere, A., Calderaro, J. and Paradis, V. (2021) Combined Hepatocellular-Cholangiocarcinoma: An Update. Journal of Hepatology, 74, 1212-1224. https://doi.org/10.1016/j.jhep.2021.01.035
|
[2]
|
Morizono, S., Fukutomi, M., Yo-kota, M., et al. (2002) A Case of Combined Liver Cell and Bile Duct Carcinoma Detected 6 Years after Interferon Ther-apy for Chronic Hepatitis C, in Spite of Showing Complete Response. Nihon Shokakibyo Gakkai Zasshi, 99, 505-510.
|
[3]
|
Goodman, Z.D., Ishak, K.G., Langloss, J.M., et al. (1985) Combined Hepatocellular-Cholangiocarcinoma. A Histologic and Immunohistochemical Study. Cancer, 55, 124-135.
https://doi.org/10.1002/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO;2-Z
|
[4]
|
Nagtegaal, I.D., Odze, R.D., Klimstra, D., et al. (2020) The 2019 WHO Classification of Tumours of the Digestive System. Histo-pathology, 76, 182-188. https://doi.org/10.1111/his.13975
|
[5]
|
Fong, Y., Sun, R.L., Jarnagin, W., et al. (1999) An Analysis of 412 Cases of Hepatocellular Carcinoma at a Western Center. Annals of Surgery, 229, 790-799. https://doi.org/10.1097/00000658-199906000-00005
|
[6]
|
Zhou, Y.M., Zhang, X.F., Wu, L.P., et al. (2014) Risk Factors for Combined Hepatocellular-Cholangiocarcinoma: A Hospital-Based Case-Control Study. World Journal of Gastroenterology, 20, 12615-12620.
https://doi.org/10.3748/wjg.v20.i35.12615
|
[7]
|
Lee, C.H., Hsieh, S.Y., Chang, C.J., et al. (2013) Comparison of Clinical Characteristics of Combined Hepatocellular-Cholangiocarcinoma and Other Primary Liver Cancers. Journal of Gastroenterology and Hepatology, 28, 122-127.
https://doi.org/10.1111/j.1440-1746.2012.07289.x
|
[8]
|
Tao, C.Y., Liu, W.R., Jin, L., et al. (2018) Surgical Treat-ment of Combined Hepatocellular-Cholangiocarcinoma Is as Effective in Elderly Patients as It Is in Younger Patients: A Propensity Score Matching Analysis. Journal of Cancer, 9, 1106-1112. https://doi.org/10.7150/jca.23921
|
[9]
|
Jarnagin, W.R., Weber, S., Tickoo, S.K., et al. (2002) Combined Hepatocel-lular and Cholangiocarcinoma: Demographic, Clinical, and Prognostic Factors. Cancer, 94, 2040-2046. https://doi.org/10.1002/cncr.10392
|
[10]
|
Aoki, K., Takayasu, K., Kawano, T., et al. (1993) Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Clinical Features and Computed Tomographic Findings. Hepatology, 18, 1090-1095.
https://doi.org/10.1002/hep.1840180512
|
[11]
|
Fowler, K.J., Sheybani, A., Parker, R.A., et al. (2013) Combined Hepatocellular and Cholangiocarcinoma (Biphenotypic) Tumors: Imaging Features and Diagnostic Accuracy of Con-trast-Enhanced CT and MRI. American Journal of Roentgenology, 201, 332-339. https://doi.org/10.2214/AJR.12.9488
|
[12]
|
Brunt, E., Aishima, S., Clavien, P.A., et al. (2018) cHCC-CCA: Con-sensus Terminology for Primary Liver Carcinomas with both Hepatocytic and Cholangiocytic Differentation. Hepatology, 68, 113-126. https://doi.org/10.1002/hep.29789
|
[13]
|
De Jong, M.C., Nathan, H., Sotiropoulos, G.C., et al. (2011) Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. Journal of Clinical Oncology, 29, 3140-3145. https://doi.org/10.1200/JCO.2011.35.6519
|
[14]
|
Mason, W.S., Gill, U.S., Litwin, S., et al. (2016) HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology, 151, 986-998.e4.
https://doi.org/10.1053/j.gastro.2016.07.012
|
[15]
|
Pollicino, T. and Caminiti, G. (2021) HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 13, 368. https://doi.org/10.3390/v13030368
|
[16]
|
Connell, L.C., Harding, J.J., Shia, J., et al. (2016) Combined Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Chinese Clinical Oncology, 5, 66. https://doi.org/10.21037/cco.2016.10.02
|
[17]
|
Tickoo, S.K., Zee, S.Y., Obiekwe, S., et al. (2002) Combined Hepa-tocellular-Cholangiocarcinoma: A Histopathologic, Immunohistochemical, and in Situ Hybridization Study. The American Journal of Surgical Pathology, 26, 989-997.
https://doi.org/10.1097/00000478-200208000-00003
|
[18]
|
Li, R., Yang, D., Tang, C.L., et al. (2016) Combined Hepatocellular Carcinoma and Cholangiocarcinoma (Biphenotypic) Tumors: Clinical Characteristics, Imaging Features of Contrast-Enhanced Ultrasound and Computed Tomography. BMC Cancer, 16, Article No. 158. https://doi.org/10.1186/s12885-016-2156-x
|
[19]
|
Cui, K., Ou, Y., Shen, Y., et al. (2020) Clinical Value of Circu-lating Tumor Cells for the Diagnosis and Prognosis of Hepatocellular Carcinoma (HCC): A Systematic Review and Me-ta-Analysis. Medicine (Baltimore), 99, e22242.
https://doi.org/10.1097/MD.0000000000022242
|
[20]
|
Trevisan Franca de Lima, L., Broszczak, D., Zhang, X., et al. (2020) The Use of Minimally Invasive Biomarkers for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Bio-chimica et Biophysica Acta—Reviews on Cancer, 1874, Article ID: 188451. https://doi.org/10.1016/j.bbcan.2020.188451
|
[21]
|
Garancini, M., Goffredo, P., Pagni, F., et al. (2014) Combined Hepatocellular-Cholangiocarcinoma: A Population-Level Analysis of an Uncommon Primary Liver Tumor. Liver Trans-plantation, 20, 952-959.
https://doi.org/10.1002/lt.23897
|
[22]
|
Agrawal, S. and Belghiti, J. (2011) Oncologic Resection for Malignant Tu-mors of the Liver. Annals of Surgery, 253, 656-665. https://doi.org/10.1097/SLA.0b013e3181fc08ca
|
[23]
|
Ma, K.W. and Chok, K.S.H. (2017) Importance of Surgical Margin in the Outcomes of Hepatocholangiocarcinoma. World Journal of Hepatology, 9, 635-641. https://doi.org/10.4254/wjh.v9.i13.635
|
[24]
|
Kassahun, W.T. and Hauss, J. (2008) Management of Combined Hepatocellular and Cholangiocarcinoma. International Journal of Clinical Practice, 62, 1271-1278. https://doi.org/10.1111/j.1742-1241.2007.01694.x
|
[25]
|
Kim, K.H., Lee, S.G., Park, E.H., et al. (2009) Surgical Treatments and Prognoses of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma. An-nals of Surgical Oncology, 16, 623-629.
https://doi.org/10.1245/s10434-008-0278-3
|
[26]
|
Vauthey, J.N., Pawlik, T.M., Abdalla, E.K., et al. (2004) Is Ex-tended Hepatectomy for Hepatobiliary Malignancy Justified? Annals of Surgery, 239, 722-730. https://doi.org/10.1097/01.sla.0000124385.83887.d5
|
[27]
|
Sasaki, A., Kawano, K., Aramaki, M., et al. (2001) Clinicopathologic Study of Mixed Hepatocellular and Cholangiocellular Carcinoma: Modes of Spreading and Choice of Surgical Treatment by Reference to Macroscopic Type. Journal of Surgical Oncology, 76, 37-46.
https://doi.org/10.1002/1096-9098(200101)76:1<37::AID-JSO1007>3.0.CO;2-0
|
[28]
|
Vilchez, V., Shah, M.B., Daily, M.F., et al. (2016) Long-Term Outcome of Patients Undergoing Liver Transplantation for Mixed Hepatocellular Carcinoma and Cholangiocarcinoma: An Analysis of the UNOS Database. HPB (Oxford), 18, 29-34. https://doi.org/10.1016/j.hpb.2015.10.001
|
[29]
|
Dageforde, L.A., Vachharajani, N., Tabrizian, P., et al. (2021) Mul-ti-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. Journal of the American College of Surgeons, 232, 361-371. https://doi.org/10.1016/j.jamcollsurg.2020.11.017
|
[30]
|
Zhang, G., Chen, B.W., Yang, X.B., et al. (2022) Prognos-tic Analysis of Patients with Combined Hepatocellular-Cholangiocarcinoma after Radical Resection: A Retrospective Multicenter Cohort Study. World Journal of Gastroenterology, 28, 5968-5981. https://doi.org/10.3748/wjg.v28.i41.5968
|
[31]
|
Malik, I.A., Rajput, M., Werner, R., et al. (2022) Differential in Vitro Effects of Targeted Therapeutics in Primary Human Liver Cancer: Importance for Combined Liver Cancer. BMC Cancer, 22, Article No. 1193.
https://doi.org/10.1186/s12885-022-10247-6
|
[32]
|
Weber, S.M., Ribero, D., O’reilly, E.M., et al. (2015) Intrahe-patic Cholangiocarcinoma: Expert Consensus Statement. HPB (Oxford), 17, 669-680. https://doi.org/10.1111/hpb.12441
|